Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nektar Therapeutics

0.7751
+0.03684.98%
Post-market: 0.77510.00000.00%19:52 EDT
Volume:3.16M
Turnover:2.48M
Market Cap:144.25M
PE:-1.34
High:0.8113
Open:0.7533
Low:0.7406
Close:0.7383
Loading ...

Company Profile

Company Name:
Nektar Therapeutics
Exchange:
NASDAQ
Establishment Date:
1990
Employees:
61
Office Location:
455 Mission Bay Boulevard South,San Francisco,California,United States
Zip Code:
94158
Fax:
415 339 5300
Introduction:
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Directors

Name
Position
Howard W. Robin
Director,President and Chief Executive Officer
Robert B. Chess
Chairman
Jeffrey R. Ajer
Director
Karin Eastham
Director
Myriam J. Curet
Director
R. Scott Greer
Director
Roy A. Whitfield
Director

Shareholders

Name
Position
Howard W. Robin
Director,President and Chief Executive Officer
Gil M. Labrucherie
Chief Operating Officer and Chief Financial Officer
Jillian B. Thomsen
Senior Vice President, Finance and Chief Accounting Officer
John Northcott
Senior Vice President and Chief Commercial Officer
Mark A. Wilson
Senior Vice President and General Counsel
Jonathan Zalevsky
Chief Research and Development Officer